## **MALIGNANT PLEURAL MESOTHELIOMA**


# AT-A-GLANCE

Mesothelioma is a rare type of cancer most often caused by asbestos that affects the smooth lining of the chest, lungs, heart, and abdomen. The layer of tissue surrounding these organs is made up of mesothelial cells, hence the name mesothelioma. Pleural mesothelioma is the most common type of mesothelioma. This disease affects the pleura, which is the thin balloon shaped lining of the lungs.<sup>1, 2</sup>

### INCIDENCE



new cases of mesothelioma annually



Over 70% of people diagnosed with mesothelioma have been exposed to asbestos.<sup>1, 3</sup>




Pleural is the most common type of mesothelioma, representing 70–90% of all mesothelioma cases.<sup>2</sup>

#### WHO'S AT RISK?


in the U.S.<sup>3</sup>



Mesothelioma incidence is approximately 4x higher among men.4




Some of the industries where workers are exposed to asbestos include shipbuilding, construction, manufacturing, mining.<sup>5</sup>



The incidence of mesothelioma is over 17 times higher for people older than 65 compared to people younger than 50.4


## LATENCY PERIOD AND SYMPTOMS



Malignant pleural mesothelioma causes symptoms, such as chest pain and shortness of breath, that are frustratingly similar to those of more common illnesses. These non-specific symptoms can contribute to delayed diagnosis.6,7

#### TREATMENT OVERVIEW







First-line treatment options in mesothelioma consist of surgery, chemotherapy, and radiation therapy.<sup>1</sup>

Less than 30% of malignant pleural mesothelioma patients receive surgery.<sup>6,8</sup>

In 2004, pemetrexed + cisplatin was approved for unresectable malignant pleural mesothelioma, the last treatment to have been approved until 2019.9,10

### NEW TREATMENT OPTION MAY IMPROVE OUTCOMES

A wearable and portable device is the first FDA-approved mesothelioma treatment in more than 15 years.<sup>9, 10</sup>

#### Sources

1. Rossini M, Rizzo P, Bononi I, et al. New perspectives on diagnosis and therapy of malignanct pleural mesothelioma. Front Oncol. 2018;8:91. 2. Hiriart E, Deepe R, Wessels A Mesothelium and malignant mesothelioma. J Dev Biol. 2019;7:7. 3. Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4) 491-496. 4. North American Association of Central Cancer Registries. NAACCR Fast Stats: 2012-2016 Cancer Incidence Data for Mesothelioma. https://faststats.naaccr.org/selections.php? series=cancer. Accessed August 19, 2019. 5. Butnor KJ, Sharma A, Sporn TA, Roggli VL. Malignant mesothelioma and occupational exposure to asbestos: an analysis of 1445 cases Ann Occup Hyg. 2002;46(Suppl 1):150–153. 6. Beebe-Dimmer JL, Fryzek JP, Yee CL, et al. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016;8:743-750. 7. Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018;19(3):e161-e72. 8. Flores RM, Riedel E, Donington JS, et al. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol. 2010;5(10):1649-1654. 9. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta®). Oncologist. 2004;9(5):482-488. 10. Ceresoli GL, Aerts JG, Dziadziuszko R, et al., Tumour-Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm, prospective, phase 2 trial. Lancet Oncol. 2019; Oct 9. doi: https://doi.org/10.1016/ S1470-2045(19)30532-7. [Epub ahead of print]

© 2019 Novocure. All rights reserved. Novocure is a registered trademark of Novocure. US-OPT-02702

